Report

Version of Safety Report ID3Safety Report ID11218856primarysourcecountryUSoccurcountryUStransmissiondateformat102transmissiondate28/04/2017reporttype1serious1seriousnessother1receivedateformat102Date Received25/06/2015receiptdateformat102Date Last Updated06/03/2017fulfillexpeditecriteria1companynumbUS-ELI_LILLY_AND_COMPANY-US201506006839duplicate1

Report Duplicate

duplicatesourceELI LILLY AND COduplicatenumbUS-ELI_LILLY_AND_COMPANY-US201506006839

Primary Source

reportercountryUSqualification1

Sender

sendertype2senderorganizationFDA-Public Use

Receiver

receivertype6receiverorganizationFDA

Patient

Weight101.59SexFemale

Reaction

1)

reactionmeddraversionpt19.1ReactionMood swingsOutcomeUnknown

2)

reactionmeddraversionpt19.1ReactionDrug withdrawal syndromeOutcomeUnknown

3)

reactionmeddraversionpt19.1ReactionPhotosensitivity reactionOutcomeUnknown

4)

reactionmeddraversionpt19.1ReactionParaesthesiaOutcomeUnknown

5)

reactionmeddraversionpt19.1ReactionInsomniaOutcomeUnknown

6)

reactionmeddraversionpt19.1ReactionNightmareOutcomeUnknown

7)

reactionmeddraversionpt19.1ReactionHeadacheOutcomeUnknown

8)

reactionmeddraversionpt19.1ReactionHyperhidrosisOutcomeUnknown

9)

reactionmeddraversionpt19.1ReactionAffect labilityOutcomeUnknown

Drug

1)

drugcharacterization2medicinalproductVOLTARENdrugstructuredosagenumb50drugstructuredosageunit003drugseparatedosagenumb3drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetext50 MG, TIDdrugadministrationroute048drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugadditional3

activesubstance

activesubstancenameDICLOFENAC SODIUM

openFDA Info on Medication

Application NumberNDA022122Brand NameVOLTAREN ARTHRITIS PAINGeneric NameDICLOFENAC SODIUMManufacturersGlaxoSmithKline Consumer Healthcare Holdings (US) LLCproduct_ndc0067-8152, 0067-8153Product TypeHUMAN OTC DRUGRouteTOPICALActive IngredientsDICLOFENAC SODIUMRXCUI855633, 855635spl_id051c7983-b0ec-4d0b-8212-66415f6e3058spl_set_id30a94282-0892-442a-aa10-6525cbd4fe88Package NDC 0067-8152-01, 0067-8152-02, 0067-8152-03, 0067-8152-04, 0067-8152-05, 0067-8152- ... UNIIQTG126297Q

2)

drugcharacterization2medicinalproductJANUVIAdrugstructuredosagenumb100drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugadditional3

activesubstance

activesubstancenameSITAGLIPTIN PHOSPHATE

openFDA Info on Medication

Application NumberNDA021995Brand NameJANUVIAGeneric NameSITAGLIPTINManufacturersMerck Sharp & Dohme LLCproduct_ndc0006-0112, 0006-0221, 0006-0277Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsSITAGLIPTIN PHOSPHATERXCUI665033, 665036, 665038, 665040, 665042, 665044spl_id6679e521-e2d5-4ffe-b1e0-c4511207fabespl_set_idf85a48d0-0407-4c50-b0fa-7673a160bf01Package NDC 0006-0221-01, 0006-0221-28, 0006-0221-31, 0006-0221-54, 0006-0112-01, 0006-0112- ... UNIITS63EW8X6F

3)

drugcharacterization2medicinalproductAMARYLdrugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugadditional3

activesubstance

activesubstancenameGLIMEPIRIDE

openFDA Info on Medication

Application NumberNDA020496Brand NameAMARYLGeneric NameGLIMEPIRIDEManufacturersSanofi-Aventis U.S. LLCproduct_ndc0039-0221, 0039-0222, 0039-0223Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsGLIMEPIRIDERXCUI153591, 153843, 153845, 199245, 199246, 199247spl_idf54571bb-4a69-4326-aad3-96b1b7198b6dspl_set_id222b630b-7e09-43b4-9894-3d87f10add91Package NDC0039-0221-10, 0039-0222-10, 0039-0223-10NUIN0000175608, M0020795Established Pharmacologic ClassSulfonylurea [EPC]Chemical StructureSulfonylurea Compounds [CS]UNII6KY687524K

4)

drugcharacterization2medicinalproductAVAPROdrugstructuredosagenumb300drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugadditional3

activesubstance

activesubstancenameIRBESARTAN

openFDA Info on Medication

Application NumberNDA020757Brand NameAVAPROGeneric NameIRBESARTANManufacturersSanofi-Aventis U.S. LLCproduct_ndc0024-5850, 0024-5851, 0024-5852Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsIRBESARTANRXCUI153665, 153666, 153667, 200094, 200095, 200096spl_idcf3ca8df-5a3f-413d-a895-65685cc17313spl_set_id7885b2a8-be4e-48ab-8113-4e6ab791eb98Package NDC 0024-5850-30, 0024-5850-90, 0024-5851-30, 0024-5851-90, 0024-5852-30, 0024-5852- ... NUIN0000000070, N0000175561Mechanism of ActionAngiotensin 2 Receptor Antagonists [MoA]Established Pharmacologic ClassAngiotensin 2 Receptor Blocker [EPC]UNIIJ0E2756Z7N

5)

drugcharacterization1medicinalproductCYMBALTAdrugauthorizationnumb021427drugstructuredosagenumb60drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetext60 MG, QDdrugdosageformCAPSULEdrugadministrationroute048actiondrug6drugrecurreadministration3

activesubstance

activesubstancenameDULOXETINE HYDROCHLORIDE

openFDA Info on Medication

Application NumberNDA021427Brand NameCYMBALTAGeneric NameDULOXETINE HYDROCHLORIDEManufacturersEli Lilly and Companyproduct_ndc0002-3235, 0002-3240, 0002-3270Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsDULOXETINE HYDROCHLORIDERXCUI596926, 596928, 596930, 596932, 596934, 615186spl_id892f05de-dd11-4ae3-9a85-ce9cfcbeaaccspl_set_id2f7d4d67-10c1-4bf4-a7f2-c185fbad64baPackage NDC0002-3235-60, 0002-3240-30, 0002-3240-90, 0002-3270-30, 0002-3270-04UNII9044SC542W

6)

drugcharacterization2medicinalproductLUNESTAdrugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugadditional3

activesubstance

activesubstancenameESZOPICLONE

openFDA Info on Medication

Application NumberNDA021476Brand NameLUNESTAGeneric NameESZOPICLONEManufacturersSunovion Pharmaceuticals Inc.product_ndc63402-190, 63402-191, 63402-193Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsESZOPICLONERXCUI485440, 485442, 485465, 540407, 540409, 540411spl_id4c2704d7-3027-4240-9073-3f0b24cf15b5spl_set_idfd047b2b-05a6-4d99-95cb-955f14bf329fPackage NDC 63402-190-30, 63402-191-03, 63402-191-10, 63402-191-01, 63402-191-30, 63402-193- ... UNIIUZX80K71OE

7)

drugcharacterization2medicinalproductGLUCOPHAGEdrugstructuredosagenumb2000drugstructuredosageunit003drugdosagetext2000 MG, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugadditional3

activesubstance

activesubstancenameMETFORMIN HYDROCHLORIDE

8)

drugcharacterization2medicinalproductVYTORINdrugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugadditional3

activesubstance

activesubstancenameEZETIMIBE\SIMVASTATIN

openFDA Info on Medication

Application NumberNDA021687Brand NameVYTORINGeneric NameEZETIMIBE AND SIMVASTATINManufacturersOrganon LLCproduct_ndc78206-174, 78206-175, 78206-176, 78206-177Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsEZETIMIBE, SIMVASTATINRXCUI476345, 476349, 476350, 476351, 1245420, 1245430, 1245441, 1245449spl_ida5b011e5-bb5e-4c3e-90ee-2c040c3420f1spl_set_id89b860d2-de83-468e-b7e8-76aeec2edca2Package NDC 78206-174-01, 78206-174-02, 78206-175-01, 78206-175-02, 78206-176-01, 78206-176- ... NUIN0000175589, N0000000121, N0000008553, N0000175911Established Pharmacologic Class HMG-CoA Reductase Inhibitor [EPC], Dietary Cholesterol Absorption Inhibitor [EPC ... Mechanism of ActionHydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]Physiologic/Pharmacodynamic EffectDecreased Cholesterol Absorption [PE]UNIIAGG2FN16EV, EOR26LQQ24

9)

drugcharacterization2medicinalproductCHANTIXdrugdosagetextUNK, PRNdrugadministrationroute065actiondrug5drugadditional3

activesubstance

activesubstancenameVARENICLINE TARTRATE

openFDA Info on Medication

Application NumberNDA021928Brand NameCHANTIXGeneric NameVARENICLINE TARTRATEManufacturersU.S. Pharmaceuticals, Pfizer Labs, Division of Pfizer Inc.product_ndc63539-473, 0069-0468, 0069-0469, 0069-0471Product TypeHUMAN PRESCRIPTION DRUGRXCUI636671, 636676, 637188, 637190, 749289, 795737, 749788, 795735spl_id3e5ba0e7-3dc1-414c-a66a-042f0aa3908c, b98d3e2a-7091-4a12-9139-e0f94683292bspl_set_idd52bc40b-db7b-4243-888c-9ee95bbc6545, f0ff4f27-5185-4881-a749-c6b7a0ca5696Package NDC63539-473-10, 0069-0468-56, 0069-0469-56, 0069-0469-03, 0069-0471-03RouteORALActive IngredientsVARENICLINE TARTRATEUNII82269ASB48

10)

drugcharacterization2medicinalproductFLEXERILdrugdosagetextUNK, PRNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugadditional3

activesubstance

activesubstancenameCYCLOBENZAPRINE HYDROCHLORIDE

11)

drugcharacterization1medicinalproductCYMBALTAdrugauthorizationnumb021427drugdosagetextUNKdrugdosageformCAPSULEdrugindicationDEPRESSIONdrugstartdateformat102drugstartdate19/05/2009drugenddateformat610drugenddate/11/2012actiondrug6drugrecurreadministration3

activesubstance

activesubstancenameDULOXETINE HYDROCHLORIDE

openFDA Info on Medication

12)

drugcharacterization2medicinalproductLORCETdrugdosagetextUNK, PRNdrugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugadditional3

activesubstance

activesubstancenameACETAMINOPHEN\HYDROCODONE BITARTRATE

Adverse Event Report

Report

Report Duplicate

Primary Source

Sender

Receiver

Patient

Reaction

1)

2)

3)

4)

5)

6)

7)

8)

9)

Drug

1)

activesubstance

openFDA Info on Medication

2)

activesubstance

openFDA Info on Medication

3)

activesubstance

openFDA Info on Medication

4)

activesubstance

openFDA Info on Medication

5)

activesubstance

openFDA Info on Medication

6)

activesubstance

openFDA Info on Medication

7)

activesubstance

8)

activesubstance

openFDA Info on Medication

9)

activesubstance

openFDA Info on Medication

10)

activesubstance

11)

activesubstance

openFDA Info on Medication

12)

activesubstance

Media

Newsletter

Follow us

Connect with us